Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 9:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091716
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Cash Flows from Investing Activities | ||
| Maturities of investments | 135,000 | 210,000 |
| Purchase of investments | (185,607) | (166,619) |
| Purchase of property and equipment | (12,049) | (13,672) |
| Net cash provided by (used in) investing activities | (62,656) | 29,709 |
| Cash Flows from Financing Activities | ||
| Tax payments related to shares withheld for vested restricted stock units | (5,345) | (6,148) |
| Proceeds from the issuance of common stock under employee stock purchase plan | 861 | 669 |
Item 1.Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Iovance Biotherapeutics, Inc.'s capex?
- Iovance Biotherapeutics, Inc. (IOVA) reported capex of $5.44M in Q2 2026.
- How has Iovance Biotherapeutics, Inc.'s capex changed year-over-year?
- Iovance Biotherapeutics, Inc.'s capex decreased by 27.1% year-over-year, from $7.46M to $5.44M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s capex?
- Over 4 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s capex has grown at a -2.6% compound annual growth rate (CAGR), from $37.57M to $33.84M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Iovance Biotherapeutics, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude